loading...| Preferred Name |
Ocrelizumab |
|
| Synonyms |
|
|
| Definitions |
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C66250 |
|
| CAS_Registry |
637334-45-3 |
|
| code |
C66250 |
|
| Contributing_Source |
FDA |
|
| definition |
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning. |
|
| FDA_UNII_Code |
A10SJL62JY |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Ocrelizumab |
|
| Legacy Concept Name |
Ocrelizumab |
|
| Maps_To |
Ocrelizumab |
|
| NCI_Drug_Dictionary_ID |
780147 |
|
| PDQ_Closed_Trial_Search_ID |
780147 |
|
| PDQ_Open_Trial_Search_ID |
780147 |
|
| Preferred_Name |
Ocrelizumab |
|
| prefixIRI |
NCIT:C66250 |
|
| prefLabel |
Ocrelizumab |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1882138 |
|
| subClassOf |